The monoclonal antibody elotuzumab has been approved in combination with lenalidomide and dexamethasone since May 2016 for further treatment of multiple myeloma in adults who have received at least one previous treatment. ...
Sep 1, 2016
0
1
Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with locally advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) who have already undergone chemotherapy. ...
Aug 18, 2016
0
1
The drug combination emtricitabine/tenofovir alafenamide is approved in combination with other antiviral agents for the treatment of adults and adolescents infected with human immunodeficiency virus type 1 (HIV-1). In an ...
Aug 18, 2016
0
2
Ramucirumab (trade name: Cyramza) is a monoclonal antibody, which blocks a receptor, reducing the growth of blood vessels and so reducing blood supply to the tumours. This aims to slow the growth of the tumours. As a so-called ...
Aug 18, 2016
0
0
Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have already received chemotherapy. ...
Aug 18, 2016
0
1
Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with advanced renal cell cancer who have already undergone prior therapy. In an early benefit assessment, the German Institute ...
Aug 10, 2016
0
0
Ospemifene (tradename: Senshio) is approved for the treatment of moderate to severe symptomatic vulvovaginal atrophy (VVA) in post-menopausal women who are not candidates for local vaginal oestrogen therapy. The drug has ...
Aug 10, 2016
0
0
Already in 2014, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined in an early benefit assessment whether idelalisib offers advantages over the appropriate comparator therapy for patients with ...
Jul 6, 2016
0
0
The monoclonal antibody necitumumab has been approved since February 2016 for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing non-small cell lung cancer (NSCLC) ...
Jul 5, 2016
0
0
Ramucirumab (trade name: Cyramza) is a monoclonal antibody, which blocks a receptor, reducing the growth of blood vessels and so reducing blood supply to the tumours. This aims to slow the growth of the tumours. The German ...
Jun 3, 2016
0
0
